Gilead Sciences (NASDAQ:GILD) was downgraded by equities research analysts at Vetr from a “strong-buy” rating to a “buy” rating in a report issued on Wednesday. They currently have a $90.00 price target on the biopharmaceutical company’s stock. Vetr‘s price target would indicate a potential upside of 10.11% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the company. William Blair reiterated a “buy” rating on shares of Gilead Sciences in a research note on Thursday, October 19th. Berenberg Bank set a $96.00 target price on Gilead Sciences and gave the company a “buy” rating in a research note on Thursday, October 19th. Mizuho reiterated a “buy” rating on shares of Gilead Sciences in a research note on Friday, September 29th. JPMorgan Chase & Co. set a $85.00 target price on Gilead Sciences and gave the company a “buy” rating in a research note on Wednesday, October 25th. Finally, Maxim Group upgraded Gilead Sciences from a “hold” rating to a “buy” rating and raised their target price for the company from $73.67 to $94.00 in a research note on Thursday, November 30th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eighteen have given a buy rating to the stock. Gilead Sciences presently has a consensus rating of “Buy” and a consensus price target of $85.53.

Gilead Sciences (NASDAQ GILD) traded up $1.49 during trading on Wednesday, reaching $81.74. 11,158,092 shares of the company’s stock were exchanged, compared to its average volume of 8,030,000. The firm has a market capitalization of $106,750.00, a P/E ratio of 9.30, a PEG ratio of -1.68 and a beta of 1.13. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10. Gilead Sciences has a 1 year low of $63.76 and a 1 year high of $86.27.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.13 by $0.14. The company had revenue of $6.51 billion for the quarter, compared to analysts’ expectations of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The firm’s quarterly revenue was down 13.2% compared to the same quarter last year. During the same period last year, the business posted $2.75 earnings per share. research analysts predict that Gilead Sciences will post 8.53 EPS for the current year.

In related news, insider John F. Milligan sold 220,000 shares of Gilead Sciences stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $72.88, for a total transaction of $16,033,600.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Gregg H. Alton sold 15,000 shares of Gilead Sciences stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $74.82, for a total value of $1,122,300.00. Following the transaction, the executive vice president now directly owns 77,363 shares in the company, valued at $5,788,299.66. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 491,666 shares of company stock worth $36,442,567. Company insiders own 1.30% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in GILD. Keel Point LLC grew its stake in Gilead Sciences by 0.4% during the 1st quarter. Keel Point LLC now owns 3,111 shares of the biopharmaceutical company’s stock valued at $211,000 after acquiring an additional 11 shares in the last quarter. Annex Advisory Services LLC grew its stake in Gilead Sciences by 0.6% during the 4th quarter. Annex Advisory Services LLC now owns 2,831 shares of the biopharmaceutical company’s stock valued at $287,000 after acquiring an additional 16 shares in the last quarter. CWM LLC grew its stake in Gilead Sciences by 0.6% during the 2nd quarter. CWM LLC now owns 2,957 shares of the biopharmaceutical company’s stock valued at $247,000 after acquiring an additional 17 shares in the last quarter. Paradigm Financial Advisors LLC grew its stake in Gilead Sciences by 0.3% during the 2nd quarter. Paradigm Financial Advisors LLC now owns 8,723 shares of the biopharmaceutical company’s stock valued at $617,000 after acquiring an additional 26 shares in the last quarter. Finally, Tarbox Group Inc. grew its stake in Gilead Sciences by 0.4% during the 3rd quarter. Tarbox Group Inc. now owns 6,522 shares of the biopharmaceutical company’s stock valued at $516,000 after acquiring an additional 27 shares in the last quarter. 75.95% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This report was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/01/17/vetr-downgrades-gilead-sciences-gild-to-buy.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

To view Vetr’s full report, visit Vetr’s official website.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.